Cynata Therapeutics Limited (CYP.AX)
| Previous close | 0.2100 |
| Open | 0.1950 |
| Bid | 0.2000 x 1582700 |
| Ask | 0.2100 x 3535900 |
| Day's range | 0.2000 - 0.2100 |
| 52-week range | 0.1050 - 0.2300 |
| Volume | |
| Avg. volume | 171,642 |
| Market cap | 37.723M |
| Beta (5Y monthly) | 0.81 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0900 |
| Earnings date | 23 July 2024 - 28 July 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswirePatient Enrolment Completed in CYP-006TK Diabetic Foot Ulcer Clinical Trial
Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce the completion of patient enrolment in its Phase 1 clinical trial of CYP-006TK in diabetic foot ulcers (DFU).
PR NewswireFirst Patient Treated in Phase 2 GvHD Trial
Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, confirms that the first patient has been enrolled and treated in its Phase 2 clinical trial of CYP-001 in high-risk acute graft versus host disease (aGvHD).
PR NewswireEncouraging Initial Data from CYP-006TK Diabetic Foot Ulcer Clinical Trial
Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, has completed initial analysis of wound surface area in the first 16 patients in its Phase 1 clinical trial of CYP-006TK in diabetic foot ulcers (DFU), up to the 10-week follow-up time point.
